153 related articles for article (PubMed ID: 7590780)
1. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
[TBL] [Abstract][Full Text] [Related]
2. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).
Schultes BC; Baum RP; Niesen A; Noujaim AA; Madiyalakan R
Cancer Immunol Immunother; 1998 Jun; 46(4):201-12. PubMed ID: 9671143
[TBL] [Abstract][Full Text] [Related]
3. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
[TBL] [Abstract][Full Text] [Related]
4. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
5. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer.
Schlebusch H; Wagner U; Grünn U; Schultes B
Hybridoma; 1995 Apr; 14(2):167-74. PubMed ID: 7590775
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.
Möbus VJ; Baum RP; Bolle M; Kreienberg R; Noujaim AA; Schultes BC; Nicodemus CF
Am J Obstet Gynecol; 2003 Jul; 189(1):28-36. PubMed ID: 12861134
[TBL] [Abstract][Full Text] [Related]
8. Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13?
Reinsberg J; Krebs D
Hybridoma; 1997 Feb; 16(1):59-63. PubMed ID: 9085130
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report.
Reinartz S; Boerner H; Koehler S; Von Ruecker A; Schlebusch H; Wagner U
Hybridoma; 1999 Feb; 18(1):41-5. PubMed ID: 10211787
[TBL] [Abstract][Full Text] [Related]
10. Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres.
Ma J; Samuel J; Kwon GS; Noujaim AA; Madiyalakan R
Cancer Immunol Immunother; 1998 Sep; 47(1):13-20. PubMed ID: 9755874
[TBL] [Abstract][Full Text] [Related]
11. Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3.
Schmolling J; Reinsberg J; Wagner U; Krebs D
Hybridoma; 1995 Apr; 14(2):183-6. PubMed ID: 7590777
[TBL] [Abstract][Full Text] [Related]
12. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.
Ma J; Zhou L; Wang D
Jpn J Cancer Res; 2002 Jan; 93(1):78-84. PubMed ID: 11802811
[TBL] [Abstract][Full Text] [Related]
13. Construction and expression of a single chain antibody mimicing human ovarian cancer antigen CA125.
Li AD; Li Z; Wang YH; Zhang YM; Ma J
Cell Mol Immunol; 2006 Feb; 3(1):59-62. PubMed ID: 16549051
[TBL] [Abstract][Full Text] [Related]
14. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
[TBL] [Abstract][Full Text] [Related]
15. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma.
Wagner U; Reinsberg J; Schmidt S; Mallmann P; Schmolling J; Schultes B; Richter H; Biersack HJ; Krebs D
Cell Biophys; 1994; 24-25():237-42. PubMed ID: 7736528
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
19. OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells.
Madiyalakan R; Yang R; Schultes BC; Baum RP; Noujaim AA
Hybridoma; 1997 Feb; 16(1):41-5. PubMed ID: 9085127
[TBL] [Abstract][Full Text] [Related]
20. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
Frödin JE; Faxas ME; Hagström B; Lefvert AK; Masucci G; Nilsson B; Steinitz M; Unger P; Mellstedt H
Hybridoma; 1991 Aug; 10(4):421-31. PubMed ID: 1937495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
